Mallinckrodt (MNK) Sets New 1-Year High and Low at $13.04

Mallinckrodt (NYSE:MNK)’s share price hit a new 52-week high and low on Monday . The stock traded as low as $13.04 and last traded at $13.14, with a volume of 1689488 shares changing hands. The stock had previously closed at $13.76.

MNK has been the topic of several analyst reports. Barclays lowered shares of Mallinckrodt from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $23.00 to $20.00 in a report on Friday, February 2nd. Cantor Fitzgerald set a $42.00 price objective on shares of Mallinckrodt and gave the company a “buy” rating in a report on Tuesday, February 27th. Zacks Investment Research upgraded shares of Mallinckrodt from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th. Goldman Sachs restated a “hold” rating on shares of Mallinckrodt in a report on Monday, January 1st. Finally, ValuEngine lowered shares of Mallinckrodt from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the company’s stock. Mallinckrodt currently has an average rating of “Hold” and a consensus target price of $33.83.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.85 and a current ratio of 2.18. The firm has a market capitalization of $1,128.60, a price-to-earnings ratio of 1.79, a price-to-earnings-growth ratio of 0.33 and a beta of 1.12.

Mallinckrodt (NYSE:MNK) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.29. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The business had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. During the same period last year, the business posted $1.91 earnings per share. The firm’s quarterly revenue was down 4.5% on a year-over-year basis. equities research analysts expect that Mallinckrodt will post 6.16 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue acquired a new stake in shares of Mallinckrodt during the fourth quarter worth $129,000. Cubist Systematic Strategies LLC raised its holdings in shares of Mallinckrodt by 748.1% during the third quarter. Cubist Systematic Strategies LLC now owns 7,989 shares of the company’s stock worth $299,000 after acquiring an additional 7,047 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Mallinckrodt during the fourth quarter worth $190,000. Sciencast Management LP acquired a new stake in shares of Mallinckrodt during the fourth quarter worth $210,000. Finally, CIBC World Markets Inc. acquired a new stake in shares of Mallinckrodt during the fourth quarter worth $231,000.

WARNING: “Mallinckrodt (MNK) Sets New 1-Year High and Low at $13.04” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2018/04/25/mallinckrodt-mnk-sets-new-1-year-high-and-low-at-13-04.html.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply